Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Galectin Therapeutics Inc. (GALT)

Add GALT Price Alert      Hide Sticky   Hide Intro
Moderator: Chess Master, GREGG THE GREEK
Search This Board: 
Last Post: 8/16/2017 7:26:09 PM - Followers: 74 - Board type: Free - Posts Today: 0

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Though we do not have any current marketed products, our research and development programs, designed to ultimately help patients and their physicians, are focused on:




Fibrosis is the development of excess fibrous connective tissue in an organ when exposed to a chronic disease. The longer the disease affects the organ, the more fibrous tissue is deposited and this ultimately results in the failure of the organ. Galectin Therapeutics’ drug candidates provide a promising and exciting new approach for the treatment of fibrotic diseases, including liver, lung and kidney fibrosis. Significant unmet need exists for treatment options in fibrosis. For example, there are currently no approved medical treatments available for the millions of patients in the U.S. who have non-alcoholic steatohepatitis with advanced fibrosis – commonly known as fatty liver disease. Learn about fibrosis and our research in this area including galectin effects on liver fibrosis, lung fibrosis and kidney fibrosis.




Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumors. Research shows the potential for galectin inhibition to play an important role in cancer therapy, particularly tumor immunotherapy – an emerging treatment that enhances the activity of the immune system against cancer cells. There are more than 100 types of cancers, and for many of these cancers, few treatment options exist. Our drug candidates provide a new and complimentary approach to other drugs on the market for the treatment of cancer. Learn more about cancer and immunotherapy.


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GALT News: Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update 08/14/2017 08:15:00 AM
GALT News: Current Report Filing (8-k) 08/14/2017 08:06:52 AM
GALT News: Quarterly Report (10-q) 08/14/2017 07:53:44 AM
GALT News: Patent for Enhancing Immunotherapy in Cancer Treatment Granted to Galectin Therapeutics 07/25/2017 08:30:00 AM
GALT News: Galectin Therapeutics to Present at the Singular Research Summer Conference 07/07/2017 12:00:00 PM
#3186   Realistically probably 10 billion. Share price well biotechexpert 08/16/17 07:26:09 PM
#3185   Early 2018 for combo therapy next readout, after gss2003 08/16/17 03:30:13 PM
#3184   How much is the company worth if the jmh0602 08/16/17 01:52:31 PM
#3183   Thera are also melanoma results coming. I think Coolec78 08/15/17 07:11:42 PM
#3182   Doesn't seem very encouraging given the longs are gss2003 08/15/17 10:40:40 AM
#3181   This is now a binary event stock - Amatuer17 08/15/17 05:59:20 AM
#3180   I am not normally one that I would RyGuy 08/11/17 12:15:17 PM
#3179   Yes, why no partnerships to explore other Gal-3 gss2003 08/11/17 11:21:26 AM
#3178   We will not hear anything till Dec from Amatuer17 08/10/17 07:01:14 PM
#3177   Not hearing much on the drug.... GALT has RyGuy 08/10/17 12:42:26 PM
#3176   The extension study is open label and everyone swing4fence 08/05/17 06:42:55 PM
#3175   The next 4 1/2 months will be just Amatuer17 08/04/17 07:41:00 AM
#3174   Pretty big price drop over the past week BIGT80 08/03/17 07:47:33 PM
#3173   interesting last hour. looks to me like jmh0602 08/03/17 05:23:44 PM
#3172   What happened today? Why spiked? Coolec78 08/03/17 04:56:22 PM
#3171   No I suck at that too. IRAHopeful 08/02/17 03:52:14 PM
#3169   I read the transcript of the slingshot interview. IRAHopeful 07/31/17 03:30:23 PM
#3168   Did anyone listen to conf? Stock is taking a beating Amatuer17 07/27/17 03:53:04 PM
#3167   NASH Conf Call Tomorrow 11AM Only serious Chess Master 07/26/17 06:53:43 PM
#3166   GRMD02 will work on Immunotherapy yes but what Chess Master 07/26/17 06:47:17 PM
#3165   immuno news . question Is Galectin protein stalker rickyricks 07/25/17 10:06:57 AM
#3164   The July 13 presentation is now in the jmh0602 07/24/17 12:14:32 PM
#3163   In the PR they said recording will be Amatuer17 07/18/17 02:57:30 PM
#3162   No, not sure there is one. I thought gss2003 07/18/17 12:53:05 PM
#3161   Has anyone found the recorded webcast for the conf? Amatuer17 07/17/17 08:45:43 PM
#3160   Thanks for the article Interesting to see mention of Amatuer17 07/10/17 09:08:30 PM
#3159   article on NASH - Jim is part of jmh0602 07/10/17 02:12:46 PM
#3158   Yes they are very different trials but the Amatuer17 06/25/17 10:29:21 AM
#3157   FX and CX two very different trials. biotechexpert 06/24/17 02:26:21 AM
#3156   The failed FX trial is creating doubt in Amatuer17 06/23/17 06:14:56 AM
#3155   "This trial was designed and is being conducted jmh0602 06/22/17 08:38:16 PM
#3154   Agreed 100% no side effects and low drop Chess Master 06/19/17 08:55:30 PM
#3153   I checked the clinical study site. IRAHopeful 06/19/17 01:37:13 PM
#3152   I don't know what the symptoms are for IRAHopeful 06/19/17 12:07:58 PM
#3151   Extremely low drop out rate. Patients must biotechexpert 06/14/17 09:22:07 PM
#3150   Not a bad strategy. How much are $5 gss2003 06/14/17 12:36:44 PM
#3149   As per today's PR - yes Now the question Amatuer17 06/14/17 12:20:55 PM
#3148   We've been hearing how safe the drug is jmh0602 06/14/17 12:11:34 PM
#3147   DSMB meeting - good results on safety 68% patients Amatuer17 06/14/17 08:03:11 AM
#3146   Maybe for leverage purposes, but the need one gss2003 06/12/17 08:29:53 PM
#3145   But they act like they don't want/need a Coolec78 06/12/17 07:49:40 PM
#3144   Maybe not for the trial, but definitely for gss2003 06/10/17 10:26:45 AM
#3143   No matter what - they will need a Amatuer17 06/10/17 06:04:33 AM
#3142   With current management yes they are going to Chess Master 06/09/17 08:44:24 PM
#3141   I would imagine they will get a partner gss2003 06/09/17 04:19:56 PM
#3140   IF that happens... GREGG THE GREEK 06/09/17 04:17:15 PM
#3139   Thanks for Clarifying CM. It's all good to RyGuy 06/09/17 04:05:54 PM
#3138   If that happens - assume there will be Amatuer17 06/09/17 03:08:17 PM
#3137   I just wanted to clarify what you said. Chess Master 06/09/17 02:43:34 PM
#3136   Looks good seeing GALT back on the rise. RyGuy 06/08/17 03:39:42 PM